- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering | 1 | GlobeNewswire (USA) | ||
| Do | Peering Into Longeveron's Recent Short Interest | 1 | Benzinga.com | ||
| Mi | Longeveron announces exercise of warrants for $6.2M | 2 | Seeking Alpha | ||
| Di | Longeveron Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| Mo | Longeveron stock rallies pre-market on Alzheimer's data update | 7 | Seeking Alpha | ||
| Mo | Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC) | 5 | GlobeNewswire (USA) | ||
| Mo | Why Is Longeveron (LGVN) Stock Up 48% Today? | 3 | InvestorPlace | ||
| Mo | US STOCKS Longeveron, Novavax, Telsa | 10 | Reuters | ||
| 11.04. | Longeveron Announces Closing of $5.2 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 11.04. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.04. | Why Longeveron (LGVN) Stock Exploded Higher Today | 1 | Benzinga.com | ||
| 08.04. | Longeveron Announces Pricing of $5.25 Million Public Offering | 2 | GlobeNewswire (USA) | ||
| 08.04. | Longeveron stock rallies 75% amid public offering, business update | 3 | Seeking Alpha | ||
| 08.04. | Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals | 100 | GlobeNewswire (Europe) | MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that the Company's CEO, Wa'el Hashad... ► Artikel lesen | |
| 08.04. | Why Is Longeveron (LGVN) Stock Up 82% Today? | 4 | InvestorPlace | ||
| 03.04. | Longeveron Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 19.03. | Longeveron files to sell Class A common stock, warrants, no amount given | 2 | Seeking Alpha | ||
| 19.03. | Longeveron Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 19.03. | Longeveron Announces 1-for-10 Reverse Stock Split | 85 | GlobeNewswire (Europe) | MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs... ► Artikel lesen | |
| 19.03. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings |
Seite:
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,55 | -0,06 % | Biotech Report: Evotec klettern, Biontech leichter | (shareribs.com) Frankfurt / New York 12.04.2024 - Biotech-Aktien zeigen sich im deutschen Handel uneinheitlich. Evotec können zulegen, während es für 4SC und Qiagen abwärts geht. An der Wall Street... ► Artikel lesen | |
| PAION | 0,029 | -22,63 % | Schock-News für Paion Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
| MODERNA | 94,70 | -1,19 % | Moderna: DARAUF wird es nächste Woche ankommen! | Grund zum Feiern haben heute alle Moderna-Aktionäre. Denn für den Kurs ergibt sich im Vergleich zur Vorwoche ein Plus von 3,30 Prozent. Der Titel schloss zwei der fünf Sitzungen mit Gewinnen. Am Dienstag... ► Artikel lesen | |
| EPIGENOMICS | 1,595 | -2,45 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,920 | -2,54 % | KI im Gesundheitswesen mit evotec, Defence Therapeutics, Bayer: Revolutionäre Fortschritte und medizinische Durchbrüche | Im Gesundheitswesen nimmt Künstliche Intelligenz (KI) immer mehr an Fahrt auf. KI-basierte Systeme können medizinische Datenbanken nutzen, um in der Forschung kostbare Zeit zu sparen, die es Unternehmen... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,925 | 0,00 % | Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products | IGDI will leverage Ginkgo's Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON, April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,310 | 0,00 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,975 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA | Requested for Q2 2024, the Type C meeting is to focus on planned registration-enabling trial in HR+/HER2- metastatic breast cancer
Overall survival results from the randomized HR+/HER2- metastatic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,400 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion's Board of DirectorsSALT LAKE... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 3,460 | -3,22 % | Anavex Life Sciences Corp.: Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX3-71 in Schizophrenia | First patient screened ahead of schedule Trial to investigate positive, negative, and cognitive domains of schizophrenia ANAVEX®3-71's differentiated dual novel mechanism of action offers the potential... ► Artikel lesen | |
| ASSERTIO | 0,754 | 0,00 % | Assertio Holdings, Inc.: Assertio Reports Fourth Quarter and Full Year 2023 Financial Results | Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million 2024 Full Year Outlook for Net Product Sales of $110 to $125 Million, Adjusted EBITDA of... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 26,310 | 0,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| CERUS | 1,619 | +4,72 % | Cerus gains as Craig Hallum launches at Buy on return to growth | ||
| SIGA TECHNOLOGIES | 8,240 | 0,00 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,680 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen |
Das Unternehmen LONGEVERON INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
